Elanco Animal Health (NYSE:ELAN) Given New $29.00 Price Target at KeyCorp

Elanco Animal Health (NYSE:ELAN) had its price target raised by stock analysts at KeyCorp from $27.00 to $29.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price target would suggest a potential upside of 6.60% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Leerink Partners upped their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. raised their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Barclays started coverage on Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, UBS Group boosted their price objective on Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.44.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $0.83 on Wednesday, reaching $27.21. 640,983 shares of the company’s stock traded hands, compared to its average volume of 4,575,653. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $27.69. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The firm has a market cap of $13.52 billion, a price-to-earnings ratio of 453.93, a P/E/G ratio of 3.69 and a beta of 1.87. The stock has a 50 day moving average price of $23.97 and a 200-day moving average price of $21.62.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period last year, the firm earned $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities research analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, CFO Robert M. Vanhimbergen purchased 6,950 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $21.64 per share, with a total value of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev A. Modi acquired 4,500 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average cost of $21.33 per share, with a total value of $95,985.00. Following the transaction, the insider directly owned 123,082 shares in the company, valued at $2,625,339.06. This trade represents a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 43,450 shares of company stock worth $937,883 over the last quarter. 0.89% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the business. Kera Capital Partners Inc. increased its holdings in shares of Elanco Animal Health by 79.0% in the 4th quarter. Kera Capital Partners Inc. now owns 21,735 shares of the company’s stock valued at $523,000 after acquiring an additional 9,595 shares during the period. T. Rowe Price Investment Management Inc. grew its position in Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares during the last quarter. Compound Planning Inc. increased its stake in Elanco Animal Health by 29.7% in the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock valued at $482,000 after purchasing an additional 4,876 shares during the period. Invesco Ltd. increased its stake in Elanco Animal Health by 336.0% in the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares during the period. Finally, Corient Private Wealth LLC boosted its stake in shares of Elanco Animal Health by 122.3% during the fourth quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock worth $3,743,000 after buying an additional 90,993 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 beat and stronger 2026 targets — Elanco reported Q4 revenue of $1.144B (+12% yr/yr) and adjusted EPS of $0.13, beating estimates; it set FY2026 revenue guidance of $4.95–5.02B, raised its 2026 innovation revenue target to $1.15B, and guided adjusted EPS $1.00–1.06 while targeting lower net leverage. Elanco Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade — Leerink Partners raised its price target on ELAN to $30 and kept an outperform rating, signaling institutional confidence in the outlook and providing upside to the share valuation. Leerink raises price target to $30 (Benzinga)
• Positive Sentiment: Shares hit recent highs — Coverage noted ELAN reached a 52‑week high after the Q4 print and 2026 outlook, reflecting positive market reaction to growth/guidance beats. Elanco hits 52-week high after Q4 results (Seeking Alpha)
• Neutral Sentiment: CEO media appearance — CEO Jeff Simmons spoke one‑on‑one with Jim Cramer (visibility event) to discuss the quarter, strategy and the “Big 6” product rollouts — useful for investor messaging but not a direct financial driver. Elanco CEO Jeff Simmons on Jim Cramer (CNBC)
• Neutral Sentiment: Earnings materials available — The earnings slide deck and call transcript provide granular metrics (adjusted EBITDA margin, innovation revenue breakdown, product momentum) for investors doing deeper fundamental work. Q4 2025 earnings call transcript (Seeking Alpha)
• Negative Sentiment: Margin pressure flagged — Several outlets highlighted concerns around margins and short‑term profitability (and some noted the stock initially slipped on those worries), pointing to investor focus on whether margin recovery will match top‑line gains. Elanco beats estimates but shares edge down on margin concerns (Investing.com)

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.